Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"

Current Controlled Trials in Cardiovascular Medicine

Volumn 2, Issue 1, 2001, Pages 8-11

  Fazio, Sergio ^a   Linton, MacRae F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Clinical trials; Coronary disease prevention; Coronary heart disease risk; Low density lipoprotein cholesterol; Meta analyses; Statins

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIET; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; NOTE; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE;

EID: 0035106304     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-2-1-008     Document Type: Note

References (30)

1. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study
2. Cholesterol reduction yields clinical benefit
3. Effects of lipid lowering therapy on progression of coronary and carotid artery disease
4. Report of the Conference on Low Blood Cholesterol: Mortality associations
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
6. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
8. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
9. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
10. Longevity syndromes: Familial hypobeta and familial hyperalpha lipoproteinemia
11. Familial hypobetalipoproteinemia
12. A receptor-mediated pathway for cholesterol homeostasis
13. Cholesterol reduction and clinical benefit Are there limits to our expectations?
14. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
15. Atherosclerosis and arterial influx of lipoproteins
16. Atherosclerosis - An inflammatory disease
17. Intensive blood-glucose control with sulhonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
18. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)
20. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the scandinavian simvastatin survival study
21. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
22. Baseline serum cholesterol and treatment effect in the scandinavian simvastatin survival study
23. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
24. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: Absolute levels or extent of lowering?
25. Current perspectives on statins
26. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients
27. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs